Delivery Order SPE2DR25D2014-SPE2DR26FZ95L
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Brilinta 60 mg tablets (60-count units) with a ceiling value of $10,406.56. This firm fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The award carries no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Brilinta 90 mg on August 5, 2025, with a ceiling value of $1,468.41. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,340.64 to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (60-count units) on December 22, 2025, with an ultimate completion date of December 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Brilinta 60 mg tablets (60-count units) valued at $1,211.20 under a firm fixed-price contract type. This delivery order, which is a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX, valued at $999.999 billion through December 2026), represents a competitively awarded, non-set-aside procurement. The place...
- The Defense Logistics Agency awarded a delivery order valued at $1,926.42 to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (quantity 60s) on August 26, 2025, with completion scheduled for August 27, 2025. This firm fixed price delivery order represents a non-set-aside award executed through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Brilinta 90 mg tablets in a 60-count package at a ceiling value of $1,655.80. This firm fixed-price delivery order, with an ultimate completion date of October 27, 2025, represents a competitive award with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award is a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,682.57 by the Defense Logistics Agency (DLA) on December 5, 2025, for the supply of Brilinta 90 mg tablets (60-count packages). The contract carries a firm fixed price structure with an ultimate completion date of December 8, 2025, and was awarded on a competitive basis with no set-aside designation. This delivery order is issued under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Brilinta 60 mg tablets (60-count) on November 3, 2025, with an ultimate completion date of November 4, 2025. This firm fixed price delivery order, valued at $1,516.38, represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Brilinta 90 mg tablets (60-count units) valued at $1,796.80 with a firm fixed price structure. The award, issued on November 12, 2025, represents a non-competitive delivery order with an ultimate completion date of November 13, 2025. This order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vendor agreement running through...
- The Defense Logistics Agency awarded a delivery order valued at $2,350.29 to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (60-count packages) on April 25, 2025, with completion scheduled for April 28, 2025. This firm fixed price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026....
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ95LDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Brilinta 60 mg tablets on December 11, 2025, with a ceiling value of $3,517.92 and an ultimate completion date of December 12, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order supports the federal military healthcare supply chain by providing Brilinta, a brand-name antiplatelet medication used in cardiovascular treatment. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The company's IDC with DLA enables flexible fulfillment of pharmaceutical needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, demonstrating its established capability to meet federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 12/10/25 |